Pfizer's New Breast Cancer Drug Cuts Disease Risk by 40%

Pfizer's experimental drug combination reduced cancer progression risk by 40% in patients whose breast cancer returned after standard treatment.

The breakthrough offers new hope for hard-to-treat cases where current therapies have failed.